Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.37 USD | -0.88% | -7.13% | +31.46% |
02-09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
02-07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Business Summary
Number of employees: 145
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule Drugs
100.0
%
| 86 | 100.0 % | 79 | 100.0 % | -8.07% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 86 | 100.0 % | 79 | 100.0 % | -8.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 30/06/03 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 31/08/03 |
Chief Tech/Sci/R&D Officer | 50 | 07/08/22 | |
Yat Sun Or
CTO | Chief Tech/Sci/R&D Officer | 72 | 31/10/99 |
Jennifer Viera
IRC | Investor Relations Contact | - | 31/12/22 |
Brendan Luu
PRN | Corporate Officer/Principal | 49 | 25/01/21 |
Tara Kieffer
PRN | Corporate Officer/Principal | 46 | 07/12/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 28/06/20 |
Lesley Russell
BRD | Director/Board Member | 63 | 17/11/16 |
Bruce Carter
CHM | Chairman | 80 | 24/11/13 |
Jay Luly
CEO | Chief Executive Officer | 67 | 30/06/03 |
Terry Vance
BRD | Director/Board Member | 67 | 31/05/11 |
Yujiro Hata
BRD | Director/Board Member | 49 | 18/08/21 |
Director/Board Member | 64 | 12/09/17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 21,155,983 | 19,865,549 ( 93.90 %) | 0 | 93.90 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.46% | 262M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ENTA Stock
- Company Enanta Pharmaceuticals, Inc.